Fed. Circ. Says Analysis Lacking In Nix Of Quillivant IP
The Federal Circuit ruled Tuesday that a Delaware federal court failed to adequately explain why it invalidated patent claims covering Tris Pharma Inc.'s ADHD treatment Quillivant XR, breathing new life into...To view the full article, register now.
Already a subscriber? Click here to view full article